Cargando…

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and its role in the development of de novo resistance to targeted therapies has become increasingly apparent. However, the mechanisms of microenvironment-mediated drug resistance for nonspecific convention...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonçalves-Ribeiro, Samuel, Díaz-Maroto, Natalia Guillen, Berdiel-Acer, Mireia, Soriano, Antonio, Guardiola, Jordi, Martínez-Villacampa, Mercedes, Salazar, Ramon, Capellà, Gabriel, Villanueva, Alberto, Martínez-Balibrea, Eva, Molleví, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312347/ https://www.ncbi.nlm.nih.gov/pubmed/27517495 http://dx.doi.org/10.18632/oncotarget.11121

Ejemplares similares

A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer
por: Berdiel-Acer, Mireia, et al.
Publicado: (2014)

PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts
por: Molleví, David G, et al.
Publicado: (2009)

IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment
por: Maia, Ana, et al.
Publicado: (2021)

The Blockade of Tumoral IL1β-Mediated Signaling in Normal Colonic Fibroblasts Sensitizes Tumor Cells to Chemotherapy and Prevents Inflammatory CAF Activation
por: Díaz-Maroto, Natalia Guillén, et al.
Publicado: (2021)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts
por: Berdiel-Acer, Mireia, et al.
Publicado: (2021)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay
por: Gunnlaugsson, Adalsteinn, et al.
Publicado: (2009)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer
por: Li, Qing-Fang, et al.
Publicado: (2010)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis
por: Kemmer, Svenja, et al.
Publicado: (2022)

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
por: Stoehlmacher, J, et al.
Publicado: (2004)

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines
por: Ginés, Alba, et al.
Publicado: (2015)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance
por: Pelullo, Maria, et al.
Publicado: (2022)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer†
por: Chitapanarux, I, et al.
Publicado: (2011)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective
por: Sisic, Leila, et al.
Publicado: (2023)

Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin
por: Bommer, Ulrich-Axel, et al.
Publicado: (2017)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
por: Basso, Valeria, et al.
Publicado: (2019)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
por: Calls, Aina, et al.
Publicado: (2022)

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2016)

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy
por: Li, Sheng, et al.
Publicado: (2014)

Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
por: Martinez-Bernabe, Toni, et al.
Publicado: (2023)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
por: Glatz, Torben, et al.
Publicado: (2020)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

FuSuMaTech workshop
por: Olofsson, Simon
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8ql192e3uvf57pussk8uk6dsuj